Research Review Proposes CRF-Mitochondria-Inflammation-Senescence Axis in Stress-Induced Brain Aging

A newly proposed biological model links corticotropin-releasing factor (CRF) signaling directly to mitochondrial fragmentation and chronic neuroinflammation, providing a theoretical framework for how chronic stress accelerates cellular senescence in the aging brain.

A review article published in Frontiers in Aging Neuroscience proposes a conceptual framework integrating CRF signaling with mitochondrial dysfunction, chronic neuroinflammation, and cellular senescence.

The authors report that sustained CRFR1-mediated signaling impairs mitochondrial dynamics, inducing Drp1-dependent fission, calcium overload, ROS generation, and mitochondrial DNA (mtDNA) damage.

According to the review, cytosolic leakage of damaged mtDNA subsequently triggers cGAS-STING and NLRP3 inflammasome pathways, driving type I interferon and IL-1beta-mediated chronic inflammaging.

Sustained neuroinflammation is shown to promote a senescence-like phenotype in post-mitotic neurons and secretory SASP in glial cells, which in turn reinforces hypothalamic-pituitary-adrenal (HPA) axis hyperactivity.

The authors discuss potential therapeutic interventions targeting this axis, including CRFR1 antagonists, mitochondrial-targeted antioxidants like SS-31 (elamipretide), and targeted senescent cell clearance.

The proposed 'CRF-mitochondria-inflammation-senescence' axis provides a cohesive, sequential mechanism illustrating how neuroendocrine stress signals translate into biological hallmarks of aging.

The model suggests that CRF-mediated aging occurs not only centrally but also through local paracrine and autocrine stress signaling within both brain circuits and peripheral tissues, such as skin and hair follicles.

Identifying upstream signaling nodes like CRFR1 could provide integrated, multi-system diagnostic biomarkers that reflect psychological stress, neuroendocrine activity, and cellular aging simultaneously.

The translation of CRFR1 antagonists has faced significant historical hurdles, including lipophilicity and poor pharmacokinetics in early candidates, but recent clinical developments highlight opportunities for biomarker-guided precision medicine.

The scientific integration of neuroendocrine stress pathways with mitochondrial dysfunction and cellular senescence validates therapeutic concepts that treat aging as an interconnected, multi-hallmark system rather than isolated cellular defects.

The emphasis on NLRP3 inflammasome activation as a bridge between mitochondrial damage and brain inflammaging supports the clinical rationale for developing brain-penetrant NLRP3 inhibitors.

Recent regulatory milestones, such as the FDA's late 2024 approval of crinecerfont for classical congenital adrenal hyperplasia, demonstrate that targeting the CRF-CRFR1 pathway is clinically and commercially viable, potentially lowering the translational barrier for neurodegenerative or age-related indications.

Longitudinal clinical validation studies seeking to correlate peripheral blood CRF and CRFR1 expression levels with established aging biomarkers in humans.

The clinical and preclinical development of allosteric, tissue-selective, and brain-penetrant CRFR1 modulators to mitigate the systemic side effects and pharmacokinetic limitations of early competitive antagonists.